West Pharmaceutical Services, Inc.
WST
$351.96
-$0.18-0.05%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.33B | 3.22B | 3.07B | 3.02B | 2.96B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.33B | 3.22B | 3.07B | 3.02B | 2.96B |
| Cost of Revenue | 2.10B | 2.05B | 1.97B | 1.94B | 1.92B |
| Gross Profit | 1.22B | 1.17B | 1.10B | 1.07B | 1.04B |
| SG&A Expenses | 420.10M | 402.60M | 389.70M | 365.50M | 346.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | -1.20M | 1.30M | 900.00K | 1.20M |
| Total Operating Expenses | 2.60B | 2.53B | 2.44B | 2.38B | 2.33B |
| Operating Income | 729.30M | 693.30M | 638.70M | 636.30M | 627.20M |
| Income Before Tax | 709.10M | 684.90M | 615.30M | 616.80M | 611.20M |
| Income Tax Expenses | 144.20M | 142.20M | 121.60M | 125.10M | 123.50M |
| Earnings from Continuing Operations | 564.90 | 542.70 | 493.70 | 491.70 | 487.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 564.90M | 542.70M | 493.70M | 491.70M | 487.70M |
| EBIT | 729.30M | 693.30M | 638.70M | 636.30M | 627.20M |
| EBITDA | 910.70M | 869.90M | 810.10M | 801.40M | 789.50M |
| EPS Basic | 7.87 | 7.52 | 6.83 | 6.79 | 6.72 |
| Normalized Basic EPS | 6.53 | 6.20 | 5.72 | 5.68 | 5.58 |
| EPS Diluted | 7.81 | 7.48 | 6.79 | 6.75 | 6.68 |
| Normalized Diluted EPS | 6.49 | 6.17 | 5.69 | 5.64 | 5.54 |
| Average Basic Shares Outstanding | 287.30M | 288.70M | 289.20M | 289.60M | 290.20M |
| Average Diluted Shares Outstanding | 289.00M | 290.20M | 290.80M | 291.40M | 292.20M |
| Dividend Per Share | 0.87 | 0.86 | 0.85 | 0.84 | 0.83 |
| Payout Ratio | 11.05% | 11.39% | 12.40% | 12.34% | 12.32% |